BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33415792)

  • 1. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
    Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
    Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
    Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
    Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
    J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
    Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
    PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
    Warbey VS; Ferner RE; Dunn JT; Calonje E; O'Doherty MJ
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of positron emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibroma in NF1.
    Mautner VF; Brenner W; Fünsterer C; Hagel C; Gawad K; Friedrich RE
    Anticancer Res; 2007; 27(4A):1819-22. PubMed ID: 17649778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
    Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ
    J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
    Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
    Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors.
    Friedrich RE; Nörnberg LKN; Hagel C
    Anticancer Res; 2022 May; 42(5):2327-2340. PubMed ID: 35489721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
    Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
    Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of angiogenesis in the transformation of plexiform neurofibroma into malignant peripheral nerve sheath tumors in children with neurofibromatosis type 1.
    Gesundheit B; Parkin P; Greenberg M; Baruchel S; Senger C; Kapelushnik J; Smith C; Klement GL
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):548-53. PubMed ID: 20686424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
    Friedrich RE; Kluwe L; Fünsterer C; Mautner VF
    Anticancer Res; 2005; 25(3A):1699-702. PubMed ID: 16033085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of plexiform and diffuse neurofibromas with malignant peripheral nerve sheath tumor in NF I patients: a whole-body MRI assessment.
    Attia S; Guirguis M; Le LQ; Chhabra A
    Skeletal Radiol; 2024 Apr; 53(4):769-777. PubMed ID: 37903998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plexiform neurofibroma with and without associated malignant peripheral nerve sheath tumor: a clinicopathologic and immunohistochemical analysis of 54 cases.
    McCarron KF; Goldblum JR
    Mod Pathol; 1998 Jul; 11(7):612-7. PubMed ID: 9688181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
    Salamon J; Mautner VF; Adam G; Derlin T
    Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [
    Azizi AA; Slavc I; Theisen BE; Rausch I; Weber M; Happak W; Aszmann O; Hojreh A; Peyrl A; Amann G; Benkoe TM; Wadsak W; Kasprian G; Staudenherz A; Hacker M; Traub-Weidinger T
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28771999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.
    Uthoff J; De Stefano FA; Panzer K; Darbro BW; Sato TS; Khanna R; Quelle DE; Meyerholz DK; Weimer J; Sieren JC
    J Neuroradiol; 2019 May; 46(3):179-185. PubMed ID: 29958847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion-Weighted Magnetic Resonance Imaging Improves the Accuracy of Differentiation of Benign from Malignant Peripheral Nerve Sheath Tumors.
    Koike H; Nishida Y; Ito S; Shimoyama Y; Ikuta K; Urakawa H; Sakai T; Shimizu K; Ito K; Imagama S
    World Neurosurg; 2022 Jan; 157():e207-e214. PubMed ID: 34624521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.